Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.54 |
| ▸ | SCN1A | P35498 | 3/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.40 |
| ▸ | SCN8A | Q9UQD0 | 3/20 | 0.40 |
| ▸ | CCR2 | P41597 | 4/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 7/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | CCKBR | P32239 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | ACLY | P53396 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6612260 | 0.84 | HSD11B1 (0.66) | HSD11B1SCN1ASCN5ASCN8ACCR2 | |
| SCHEMBL20899649 | 0.83 | HSD11B1 (0.40) | HSD11B1SCN1ASCN5ASCN8ACCR2 | |
| SCHEMBL6612056 | 0.81 | MCL1 (0.44) | CCR2MCL1CCKBRACLY | |
| SCHEMBL6613718 | 0.81 | HSD11B1 (0.45) | HSD11B1SCN1ASCN5ASCN8AMCL1 | |
| SCHEMBL6617119 | 0.81 | CCR2 (0.41) | HSD11B1CCR2MCL1ACLY | |
| SCHEMBL2762431 | 0.77 | HSD11B1 (0.66) | HSD11B1SCN1ASCN5ASCN8AAHR | |
| SCHEMBL5831351 | 0.77 | HSD11B1 (0.47) | HSD11B1SCN1ASCN5ASCN8AAHR | |
| SCHEMBL6609438 | 0.75 | HSD11B1 (0.66) | HSD11B1SCN1ASCN5ASCN8ACCR2 | |
| SCHEMBL5831326 | 0.75 | HSD11B1 (0.48) | HSD11B1SCN1ASCN5ASCN8AAHR | |
| SCHEMBL5831012 | 0.72 | HSD11B1 (0.70) | HSD11B1SCN1ASCN5ASCN8APPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004112779-A1 | NEW USE VII | BIOVITRUM AB (SE) | 2004-12-29 | — | — | WO | claimed |
| EP-1461333-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2004-09-29 | — | — | EP | claimed |
| US-20030130279-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2003-07-10 | — | — | US | claimed |
| WO-2003044009-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2003-05-30 | — | — | WO | claimed |
| WO-2004112779-A1 | NEW USE VII | BIOVITRUM AB (SE) | 2004-12-29 | — | — | WO | disclosed |
| EP-1461333-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2004-09-29 | — | — | EP | disclosed |
| US-20030130279-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2003-07-10 | — | — | US | disclosed |
| WO-2003044009-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130279-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD17B1, HSD3B1 | HSD11B1 1/4885SCN1A 510/4885SCN5A 953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.